Suppressing Immune-Related Toxicity and Survival in Melanoma

Researchers found that second-line immunosuppression for severe immune-related adverse events was associated with impaired survival outcomes among patients with advanced melanoma.

Related Keywords

Netherlands ,New Jersey ,United States ,Dutch ,Shailender Bhatia ,Carmana Giacomantonio ,Andrew Pecora ,Hackensack Meridian John Theurer Cancer Center ,Fred Hutchinson Cancer Center ,Celularity Inc ,Dalhousie University ,Dutch Melanoma Treatment Registry ,Hackensack Meridian ,John Theurer Cancer Center ,Nova Scotia ,Melanoma ,Malignant Melanoma ,Skin Cancer ,Alignant Skin Neoplasm ,Steroids ,Biologic Therapy ,Toxicology ,Immunocompromise ,Immunocompromised ,Malignant Kidney Neoplasm ,Kidney Cancer ,Renal Cell Cancer ,Renal Cell Carcinoma ,Ancer Kidney ,Ancer Renal Cell ,Cancer ,Alignant Neoplasia ,Arcinoma ,Adrenal Cancer ,Patient Safety ,Adverse Effects ,Side Effects ,Immunotherapy ,Anti Tnf ,Anti ,